Table 2.
Prevalence of hyperkalemia in 2016 and incidence rate of the first hyperkalemia during follow-up
| Patient category | Prevalence, /1000 population (95% CI) |
Incidence rate, /100 patient-year-at-risk (95% CI) |
||
|---|---|---|---|---|
| Total | With RAASi | Total | With RAASi | |
| Overall | 67.9 (67.1–68.8) | 142.2 (139.6–144.7) | 2.9 (2.9–2.9) | 5.9 (5.8–6.0) |
| CKD | 227.9 (224.3–231.5) | 279.1 (273.5–284.8) | 16.0 (15.8–16.2) | 19.1 (18.9–19.4) |
| Stage 1 | 72.4 (61.4–84.7) | 85.8 (65.8–109.5) | 4.8 (4.4–5.2) | 5.9 (5.3–6.5) |
| Stage 2 | 103.3 (97.4–109.4) | 113.9 (104.6–123.8) | 7.6 (7.4–7.9) | 8.7 (8.4–9.1) |
| Stage 3a | 132.2 (127.1–137.4) | 156.2 (147.9–164.7) | 9.2 (9.0–9.4) | 10.9 (10.6–11.2) |
| Stage 3b | 245.6 (237.8–253.6) | 288.0 (276.5–299.7) | 21.0 (20.5–21.4) | 23.6 (23.0–24.3) |
| Stage 4 | 436.5 (424.1–449.0) | 510.0 (492.9–527.1) | 51.7 (50.5–53.0) | 57.6 (56.0–59.3) |
| Stage 5 | 511.9 (499.1–524.8) | 627.9 (609.0–646.4) | 66.2 (64.7–67.8) | 85.5 (83.1–88.1) |
| DM | 108.4 (106.5–110.3) | 161.5 (157.8–165.2) | 5.8 (5.7–5.9) | 7.7 (7.6–7.8) |
| HF | 134.0 (131.2–136.8) | 172.7 (168.3–177.2) | 9.6 (9.5–9.7) | 11.2 (11.0–11.3) |
| HTN | 108.3 (106.7–110.0) | 136.8 (134.2–139.4) | 5.5 (5.5–5.6) | 6.5 (6.4–6.5) |
CI, confidence interval; CKD, chronic kidney disease; DM, diabetes mellitus; HF, heart failure; HTN, hypertension.